Table 1. Mean (SD) of echocardiographic variables before and 7–10 days after placebo, standard‐dose pimobendan (SD_pimo, 0.2–0.3 mg/kg PO q 12 h), and high‐dose pimobendan (HD_pimo, 0.5–0.6 mg/kg PO q 12 h) in dogs with subclinical myxomatous mitral valve disease
| Variables | Group | Before | After | p‐value (Before vs After) | % change | p‐value (% change among groups) |
|---|---|---|---|---|---|---|
| LAV (mL/kg) | Placebo | 3.0 (1.0) | 3.1 (1.2) | 0.68 | 1.3 (15.6) | 0.004 |
| SD_pimo | 2.8 (0.8) | 2.1 (0.6) | 0.002 | −22.7 (14.9)a | ||
| HD_pimo | 3.3 (1.4) | 2.4 (1.1) | <0.001 | −27.1 (16.9)a | ||
| LVVd (mL/kg) | Placebo | 4.0 (1.1) | 3.9 (0.8) | 0.1 | −0.2 (8.2) | 0.009 |
| SD_pimo | 3.8 (0.7) | 3.2 (0.7) | <0.001 | −16.7 (12.5)a | ||
| HD_pimo | 3.7 (0.8) | 2.9 (0.8) | 0.001 | −21.8 (15.0)a | ||
| LVVs (mL/kg) | Placebo | 0.86 (0.32) | 0.77 (0.29) | 0.47 | −7.3 (35.6) | <0.001 |
| SD_pimo | 0.99 (0.41) | 0.57 (0.28) | <0.001 | −41.6 (14.8)a | ||
| HD_pimo | 1.06 (0.30) | 0.48 (0.29) | <0.001 | −55.0 (20.7)a | ||
| LV EF (%) | Placebo | 78.5 (4.3) | 80.3 (6.7) | 0.49 | 2.3 (7.3) | 0.007 |
| SD_pimo | 74.4 (7.2) | 82.5 (5.4) | <0.001 | 11.3 (7.8) | ||
| HD_pimo | 71.3 (8.3) | 83.5 (8.9) | <0.001 | 17.6 (10.4)a |
LAV, left atrial volume; LVVd, left ventricular volume at end‐diastole; LVVs, left ventricular volume at end‐systole;
LV EF, left ventricular ejection fraction; SD_pimo, standard‐dose pimobendan; HD_pimo, high‐dose pimobendan.
aSignificantly different (p<0.05) compared to percent change of the placebo group.
Significant differences are in bold typeface.